Nvidia and Eli Lilly announced a $1 billion, five-year AI co-innovation lab aimed at accelerating drug discovery. The lab will combine Lilly’s expertise in biology and medicine with Nvidia’s AI, accelerated computing, and model-building capabilities.
Based in South San Francisco, the lab will co-locate scientists and engineers from both companies to develop large-scale data and AI models. Nvidia BioNeMo™ will serve as the core platform for building biomedical foundation and frontier models that enhance molecule identification, optimization, and validation.
Initial efforts will focus on a continuous learning system connecting Lilly’s wet labs with computational dry labs, enabling 24/7 AI-assisted experimentation. The lab will also explore applications across clinical development, manufacturing, and commercial operations, leveraging digital twins, agentic AI, and robotics to optimize drug production and supply chains.
The initiative expands Lilly’s AI factory, one of the pharmaceutical industry’s most powerful computing environments, and integrates Nvidia’s latest architectures, including Vera Rubin and Omniverse™ libraries. The collaboration aims to empower global biomedical research and accelerate the development of high-demand medicines while supporting startups and research ecosystems with advanced computing resources.
